Sofinnova Ventures Inc Buys Novo Nordisk A/S, Allergan PLC, Alnylam Pharmaceuticals Inc, Sells Ascendis Pharma A/S, Sanofi SA, Gilead Sciences Inc

• New Purchases: AGN, NVO, ALNY, HALO, BPMC, AKBA, INSM, TGTX, XBIT, ARQL, PTLA, ADVM,
• Added Positions: ANAB, NBIX, MGNX, BHVN, XNCR, SVRA, KDMN,
• Reduced Positions: ASND, BMRN, INCY, RETA, CLVS, HRTX, AZN, MOR, DCPH, GWPH, FGEN, ICPT, PDSB, FOLD, SNDX, KALA, DERM, FATE,
• Sold Out: SNY, GILD, TSRO, RIGL, SRPT, AIMT, PBYI, EPZM, FPRX, IMGN, CNAT, PCRX,

For the details of Sofinnova Ventures Inc's stock buys and sells, go to https://www.gurufocus.com/guru/sofinnova+ventures+inc/current-portfolio/portfolio

1. Ascendis Pharma A/S (ASND) - 998,538 shares, 12.32% of the total portfolio. Shares reduced by 33.37%
2. Amarin Corp PLC (AMRN) - 5,208,305 shares, 11.33% of the total portfolio.
3. Principia Biopharma Inc (PRNB) - 2,038,208 shares, 7.26% of the total portfolio.
4. Natera Inc (NTRA) - 3,100,560 shares, 6.70% of the total portfolio.
5. ObsEva SA (OBSV) - 4,749,623 shares, 6.37% of the total portfolio.

Sofinnova Ventures Inc initiated holding in Allergan PLC. The purchase prices were between $132.09 and $160.79, with an estimated average price of $144.95. The stock is now traded at around $136.71. The impact to a portfolio due to this purchase was 1.36%. The holding were 88,665 shares as of .

Sofinnova Ventures Inc initiated holding in Novo Nordisk A/S. The purchase prices were between $46.07 and $52.63, with an estimated average price of $49.1. The stock is now traded at around $46.94. The impact to a portfolio due to this purchase was 1.36%. The holding were 247,734 shares as of .

Sofinnova Ventures Inc initiated holding in Alnylam Pharmaceuticals Inc. The purchase prices were between $72.76 and $93.45, with an estimated average price of $83.46. The stock is now traded at around $68.07. The impact to a portfolio due to this purchase was 1.04%. The holding were 106,616 shares as of .

Sofinnova Ventures Inc initiated holding in Halozyme Therapeutics Inc. The purchase prices were between $13.94 and $17.58, with an estimated average price of $16.2. The stock is now traded at around $15.79. The impact to a portfolio due to this purchase was 0.68%. The holding were 401,329 shares as of .

Sofinnova Ventures Inc initiated holding in Blueprint Medicines Corp. The purchase prices were between $48.7 and $86.6, with an estimated average price of $73.56. The stock is now traded at around $77.20. The impact to a portfolio due to this purchase was 0.6%. The holding were 71,866 shares as of .

Sofinnova Ventures Inc initiated holding in Akebia Therapeutics Inc. The purchase prices were between $5.41 and $8.73, with an estimated average price of $6.83. The stock is now traded at around $5.79. The impact to a portfolio due to this purchase was 0.44%. The holding were 516,761 shares as of .

Sofinnova Ventures Inc added to a holding in AnaptysBio Inc by 291.48%. The purchase prices were between $61.38 and $75.39, with an estimated average price of $69.01. The stock is now traded at around $72.52. The impact to a portfolio due to this purchase was 0.56%. The holding were 97,948 shares as of .

Sofinnova Ventures Inc added to a holding in Neurocrine Biosciences Inc by 82.77%. The purchase prices were between $69.31 and $91.53, with an estimated average price of $83.53. The stock is now traded at around $78.89. The impact to a portfolio due to this purchase was 0.47%. The holding were 112,406 shares as of .

Sofinnova Ventures Inc added to a holding in Macrogenics Inc by 57.32%. The purchase prices were between $11.11 and $25.6, with an estimated average price of $17.21. The stock is now traded at around $16.27. The impact to a portfolio due to this purchase was 0.36%. The holding were 523,756 shares as of .

Sofinnova Ventures Inc added to a holding in Biohaven Pharmaceutical Holding Co Ltd by 28.23%. The purchase prices were between $34.52 and $53.29, with an estimated average price of $43.04. The stock is now traded at around $61.72. The impact to a portfolio due to this purchase was 0.15%. The holding were 124,952 shares as of .

Sofinnova Ventures Inc sold out a holding in Sanofi SA. The sale prices were between $40.83 and $45.43, with an estimated average price of $42.82.

Sofinnova Ventures Inc sold out a holding in Gilead Sciences Inc. The sale prices were between $62.53 and $70.05, with an estimated average price of $66.46.

Sofinnova Ventures Inc sold out a holding in Tesaro Inc. The sale prices were between $74.02 and $74.96, with an estimated average price of $74.7.

Sofinnova Ventures Inc sold out a holding in Rigel Pharmaceuticals Inc. The sale prices were between $2 and $2.65, with an estimated average price of $2.29.

Sofinnova Ventures Inc sold out a holding in Sarepta Therapeutics Inc. The sale prices were between $106.67 and $151.68, with an estimated average price of $128.32.

Sofinnova Ventures Inc sold out a holding in Aimmune Therapeutics Inc. The sale prices were between $21.15 and $26.37, with an estimated average price of $23.55.